Uveal melanoma natural history, complications and prognosis
|
Uveal melanoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Uveal melanoma natural history, complications and prognosis On the Web |
|
American Roentgen Ray Society Images of Uveal melanoma natural history, complications and prognosis |
|
FDA on Uveal melanoma natural history, complications and prognosis |
|
CDC on Uveal melanoma natural history, complications and prognosis |
|
Uveal melanoma natural history, complications and prognosis in the news |
|
Blogs on Uveal melanoma natural history, complications and prognosis |
|
Risk calculators and risk factors for Uveal melanoma natural history, complications and prognosis |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Simrat Sarai, M.D. [2]
Overview
Natural History
Complications
Complications of eye melanoma may include:
Glaucoma
Eye melanoma that is growing may cause glaucoma. Signs and symptoms of glaucoma may include the following:
- Eye pain
- Redness
- Blurry vision
Vision loss
Eye melanomas that are large often cause vision loss in the affected eye and may cause complications, such as retinal detachment, that also cause vision loss. If small eye melanomas occur in critical parts of the eye they may cause some vision loss. There may be difficulty seeing in the center of the vision or on the side. Advanced eye melanomas can cause complete vision loss.
Metastasis
Eye melanoma can spread outside of the eye and to distant areas of the body, including the liver, lungs and bones.
Prognosis
Poor prognostic factors for systemic disease include the follwing:
- Older age: >60 years of age[1]
- Larger tumor size[2][3][4][5][6]
- Ciliary body involvement[7]
- Presence of orange pigment overlying the tumor[2]
- Extrascleral extension[8][9][10][11]
- Histological and cytological factors associated with higher risk of metastasis includes the following:
- Cell type
- Cell type is the most commonly used predictor of outcome following enucleation, with spindle-A cell melanomas carrying the best prognosis and epithelioid cell melanomas carrying the least favorable prognosis. Nevertheless, most tumors have an admixture of cell types, and there is no clear consensus regarding the proportion of epithelioid cells that constitutes designation of a tumor as mixed or epithelioid.
- Overall survival depends on tumour size, extraocular spread, and metastases. Even small (<10 mm diameter, <3 mm thickness) tumors still carry a 10-15% 5-year mortality.
- The 10 year-survival for iris melanoma is approximately 95 percent and for ciliochoroidal tumors is 77 percent respectively.
- Several additional microscopic features can affect the prognosis of intraocular melanoma, including:[14]
- Mitotic activity.
- Lymphocytic infiltration.
- Fibrovascular loops
- Extraocular extension, recurrence, and metastasis are associated with an extremely poor prognosis, and long-term survival cannot be expected. Systemic metastases may be wide spread, with the liver > lung > bone > kidney > brain being a common sites for tumor deposits.
- The 5-year mortality rate associated with metastasis from ciliary body or choroidal melanoma is approximately 30%, compared with a rate of 2% to 3% for iris melanomas.
- The most important genetic alteration associated with poor prognosis in uveal melanoma is inactivation of BAP1, which most often occurs through mutation of one allele and subsequent loss of an entire copy of Chromosome 3 (Monosomy 3) to unmask the mutant copy.[15] Because of this function in inactivation of BAP1, monosomy 3 correlates strongly with metastatic spread.[16]
- Where BAP1 mutation status is not available, gains on chromosomes 6 and 8 can be used to refine the predictive value of the Monosomy 3 screen, with gain of 6p indicating a better prognosis and gain of 8q indicating a worse prognosis in disomy 3 tumors.[17]
- In rare instances, monosomy 3 tumors may duplicate the BAP1-mutant copy of the chromosome to return to a disomic state referred to as isodisomy.[18] Thus, isodisomy 3 is prognostically equivalent to monosomy 3, and both can be detected by tests for chromosome 3 loss of heterozygosity.[18]
- Monosomy 3, along with other chromosomal gains, losses, amplifications, and LOH, can be detected in fresh or paraffin embedded samples by virtual karyotyping.
References
- ↑ Augsburger JJ, Gamel JW (1990). "Clinical prognostic factors in patients with posterior uveal malignant melanoma". Cancer. 66 (7): 1596–600. PMID 2208011.
- ↑ 2.0 2.1 Gragoudas E, Li W, Goitein M, Lane AM, Munzenrider JE, Egan KM (2002). "Evidence-based estimates of outcome in patients irradiated for intraocular melanoma". Arch Ophthalmol. 120 (12): 1665–71. PMID 12470140.
- ↑ Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD; et al. (2005). "Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26". Arch Ophthalmol. 123 (12): 1639–43. doi:10.1001/archopht.123.12.1639. PMID 16344433.
- ↑ Shields CL, Kaliki S, Furuta M, Fulco E, Alarcon C, Shields JA (2013). "American Joint Committee on Cancer classification of posterior uveal melanoma (tumor size category) predicts prognosis in 7731 patients". Ophthalmology. 120 (10): 2066–71. doi:10.1016/j.ophtha.2013.03.012. PMID 23664467.
- ↑ Kujala E, Damato B, Coupland SE, Desjardins L, Bechrakis NE, Grange JD; et al. (2013). "Staging of ciliary body and choroidal melanomas based on anatomic extent". J Clin Oncol. 31 (22): 2825–31. doi:10.1200/JCO.2012.45.2771. PMID 23816968.
- ↑ AJCC Ophthalmic Oncology Task Force (2015). "International Validation of the American Joint Committee on Cancer's 7th Edition Classification of Uveal Melanoma". JAMA Ophthalmol. 133 (4): 376–83. doi:10.1001/jamaophthalmol.2014.5395. PMID 25555246.
- ↑ Li W, Gragoudas ES, Egan KM (2000). "Metastatic melanoma death rates by anatomic site after proton beam irradiation for uveal melanoma". Arch Ophthalmol. 118 (8): 1066–70. PMID 10922199.
- ↑ Gragoudas ES, Seddon JM, Egan KM, Polivogianis L, Hsieh CC, Goitein M; et al. (1986). "Prognostic factors for metastasis following proton beam irradiation of uveal melanomas". Ophthalmology. 93 (5): 675–80. PMID 3014416.
- ↑ Schmittel A, Bechrakis NE, Martus P, Mutlu D, Scheibenbogen C, Bornfeld N; et al. (2004). "Independent prognostic factors for distant metastases and survival in patients with primary uveal melanoma". Eur J Cancer. 40 (16): 2389–95. doi:10.1016/j.ejca.2004.06.028. PMID 15519510.
- ↑ Kleineidam M, Guthoff R, Bentzen SM (1993). "Rates of local control, metastasis, and overall survival in patients with posterior uveal melanomas treated with ruthenium-106 plaques". Radiother Oncol. 28 (2): 148–56. PMID 8248556.
- ↑ Affeldt JC, Minckler DS, Azen SP, Yeh L (1980). "Prognosis in uveal melanoma with extrascleral extension". Arch Ophthalmol. 98 (11): 1975–9. PMID 7436829.
- ↑ Robbins, Stanley L., Vinay Kumar, and Ramzi S. Cotran. Robbins and Cotran pathologic basis of disease. Philadelphia, PA: Saunders/Elsevier, 2010. Print.
- ↑ Pardo M, Dwek RA, Zitzmann N (2007). "Proteomics in uveal melanoma research: opportunities and challenges in biomarker discovery". Expert Rev Proteomics. 4 (2): 273–86. doi:10.1586/14789450.4.2.273. PMID 17425462.
- ↑ Uveal melanoma. National Cancer Institute(2015) http://www.cancer.gov/types/eye/hp/intraocular-melanoma-treatment-pdq#link/_304_toc Accessed on October 23, 2015
- ↑ Harbour JW, Onken MD, Roberson ED, Duan S, Cao L, Worley LA; et al. (2010). "Frequent mutation of BAP1 in metastasizing uveal melanomas". Science. 330 (6009): 1410–3. doi:10.1126/science.1194472. PMC 3087380. PMID 21051595.
- ↑ Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jöckel KH, Becher R (1996). "Prognostic implications of monosomy 3 in uveal melanoma". Lancet. 347 (9010): 1222–5. PMID 8622452.
- ↑ Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE (2009). "Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death". Invest Ophthalmol Vis Sci. 50 (7): 3048–55. doi:10.1167/iovs.08-3165. PMID 19182252.
- ↑ Onken MD, Worley LA, Person E, Char DH, Bowcock AM, Harbour JW (2007). "Loss of heterozygosity of chromosome 3 detected with single nucleotide polymorphisms is superior to monosomy 3 for predicting metastasis in uveal melanoma". Clin Cancer Res. 13 (10): 2923–7. doi:10.1158/1078-0432.CCR-06-2383. PMID 17504992.